Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume

Brain atrophy in multiple sclerosis (MS), as measured by percentage brain volume change (PBVC) from brain magnetic resonance imaging (MRI), has been established as an outcome parameter in clinical trials. It is unknown to what extent volume changes within different brain tissue compartments contribute to PBVC. We analyzed pairs of MRI scans (at least 6 months apart) in 600 patients with relapsing–remitting MS. Multiple regression revealed that PBVC mainly reflects volume loss of white and cortical gray matter, while deep gray matter and white matter lesions were less represented. Our findings aid the interpretation of PBVC changes in MS.

[1]  Till F. M. Andlauer,et al.  Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers , 2021, Multiple sclerosis.

[2]  C. Pozzilli,et al.  Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study , 2021, JAMA neurology.

[3]  M. Battaglini,et al.  Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization , 2021, Annals of clinical and translational neurology.

[4]  Maya B. Mathur,et al.  A Simple, Interpretable Conversion from Pearson's Correlation to Cohen's d for Continuous Exposures. , 2020, Epidemiology.

[5]  Christian Gaser,et al.  Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naïve notion? , 2019, Brain and behavior.

[6]  C. Granziera,et al.  Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis , 2019, European Neurology.

[7]  R. Chu,et al.  Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines , 2018, PloS one.

[8]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[9]  M. Battaglini,et al.  Deep grey matter volume loss drives disability worsening in multiple sclerosis , 2017, bioRxiv.

[10]  C. Enzinger,et al.  Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice , 2016, Multiple sclerosis.

[11]  Ludwig Kappos,et al.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[12]  À. Rovira,et al.  Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes , 2013, Multiple sclerosis.

[13]  M. Battaglini,et al.  Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.

[14]  F Fazekas,et al.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[15]  R. Henry,et al.  Regional grey matter atrophy in clinically isolated syndromes at presentation , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  Alan J. Thompson,et al.  Localization of grey matter atrophy in early RRMS , 2006, Journal of Neurology.

[17]  Mara Cercignani,et al.  Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. , 2006, Archives of neurology.

[18]  Marco Rovaris,et al.  Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[19]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[20]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.